Compare Natera Inc. Common Stock (NTRA) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs abrdn Physical Palladium Shares ETF — how do they compare? Natera Inc. Common Stock trades at $392.78 (market cap $57.03B), while abrdn Physical Palladium Shares ETF trades at $20.4 (market cap $602.28M). The key difference: Natera Inc. Common Stock is far larger — about 94.7× abrdn Physical Palladium Shares ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and abrdn Physical Palladium Shares ETF for 34 Days on average.
| NTRA | PALL | |
|---|---|---|
Market Cap | $57.03B | $602.28M |
Volume | 1,131,157 | 980,533 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $425.64 | $37.18 |
52-Week Low | $179.42 | $19.83 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
PALL trades at $20.38, down 1.12% with a bearish technical signal from moving averages. The ETF shows oversold conditions with RSI readings below 30, while palladium prices remain 47% below January 2026 highs. Recent news highlights potential catch-up opportunities as platinum and palladium have lagged the broader precious metals rally.
The outlook suggests contrarian opportunity as palladium approaches technical support levels, though fundamental data remains limited. Key risks include continued commodity price pressure and industrial demand uncertainty, while potential catalysts include supply constraints and renewed institutional interest in undervalued precious metals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
